妊娠期维生素D补充与母亲骨密度:MAVIDOS随机安慰剂对照试验的事后分析
MAVIDOS随机安慰剂对照试验的事后分析评估妊娠期每日1000 IU胆钙化醇对母亲产后即刻及产后4年骨密度的影响。结果显示两个干预组母亲各部位骨密度均无显著差异,产后至4年间骨密度增加1%至6%且组间相似。
要点
- 妊娠期每日1000 IU胆钙化醇未改变母亲产后2周内及平均4.1年时各部位骨密度。
- 产后2周内至产后4年母亲骨密度增加1%至6%,两组间相似。
- 该试验此前已显示对子代骨骼的益处,但母亲骨密度短期或中期无差异。
核心结论
- 尽管该试验此前已证明对子代骨骼有益,随机分配至每日1000 IU维生素D或安慰剂组的女性在短期或中期母亲骨密度无差异。
研究设计与样本
- MAVIDOS为随机安慰剂对照试验,从妊娠14至17周至分娩每日给予1000 IU胆钙化醇。
- 参与者被邀请在产后2周内及产后4年进行全身、腰椎和左髋双能X射线吸收测定法扫描。
- 在两个时间点均有双能X射线吸收测定法扫描的女性中,使用混合效应模型考虑重复测量评估胆钙化醇效应。
主要发现
- 401名参与者在产后2周内进行双能X射线吸收测定法扫描,443名参与者在平均4.1年时进行扫描。
- 与安慰剂相比,胆钙化醇补充提高了妊娠晚期血清25-羟基维生素D状态。
- 两个随机分组在所有部位、两个时间点的骨密度相似(所有p > 0.05)。
- 263名参与者在分娩时和4年时均进行双能X射线吸收测定法扫描,从产后2周内至4年骨密度增加1%至6%取决于部位,随机分组间相似。
- 在重复测量模型中,妊娠期胆钙化醇对4年时骨密度无影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The effect of pregnancy vitamin D supplementation on bone mineral density (BMD) in the mother immediately after delivery and at 4 years after delivery was assessed in a randomised placebo-controlled trial. The mothers' BMD did not differ between the two intervention groups. PURPOSE: Vitamin D supplementation during pregnancy has positive effects on the offspring's bone development and bone mineral density (BMD) in childhood, but there are limited data on the effects on the mother's skeleton. We assessed this in a post hoc follow-up of a randomised trial. METHODS: MAVIDOS was a randomised placebo-controlled trial of 1000 IU/day cholecalciferol from 14 to 17 weeks gestation until delivery. Participants were invited to have a dual-energy X-ray absorptiometry (DXA) scan of the whole body, lumbar spine (LS) and left hip within 2 weeks after delivery and again 4 years after delivery. BMD was compared between the cholecalciferol and placebo groups; in women with DXA at both time points, the effect of cholecalciferol was assessed using mixed effects modelling to account for repeated measures. RESULTS: Four hundred one and 443 participants had a DXA within 2 weeks after delivery and at a mean of 4.1 years after delivery, respectively. Cholecalciferol supplementation increased serum 25-hydroxyvitamin D status in late pregnancy compared to placebo. BMD at all sites was similar between the two randomisation groups at both time points (p > 0.05 for all). Two hundred sixty-three participants had a DXA at both birth and 4 years. BMD increased between 1 and 6% depending on the site from within 2 weeks to 4 years after delivery. This was similar between randomisation groups. The pregnancy cholecalciferol had no effect on BMD at 4 years in repeated measures modelling. CONCLUSIONS: Despite previously demonstrated benefits for the offspring skeleton in this trial, maternal BMD did not differ in the short or medium term in women randomised to 1000 IU/day vitamin D or placebo.
引用
- Moon RJ, D'Angelo S, Curtis EM, et al. Pregnancy vitamin D supplementation and bone mineral density of the mother: a post hoc analysis of the MAVIDOS randomised placebo-controlled trial. Osteoporos Int. 2025. PMID: 40549003. doi:10.1007/s00198-025-07568-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。